Related Experiment Video
Updated: Jan 21, 2026

Handling Techniques to Reduce Stress in Mice
Published on: September 25, 2021
Pharmacological Npt2a Inhibition Causes Phosphaturia and Reduces Plasma Phosphate in Mice with Normal and Reduced
Linto Thomas1, Jianxiang Xue1, Sathish Kumar Murali2
1Department of Molecular Pharmacology and Physiology, University of South Florida, Tampa, Florida; and.
Background:
The kidneys play an important role in phosphate homeostasis. Patients with CKD develop hyperphosphatemia in the later stages of the disease. Currently, treatment options are limited to dietary phosphate restriction and oral phosphate binders. The sodium-phosphate cotransporter Npt2a, which mediates a large proportion of phosphate reabsorption in the kidney, might be a good therapeutic target for new medications for hyperphosphatemia.
Methods:
The authors assessed the effects of the first orally bioavailable Npt2a inhibitor (Npt2a-I) PF-06869206 in normal mice and mice that had undergone subtotal nephrectomy (5/6 Nx), a mouse model of CKD. Dose-response relationships of sodium, chloride, potassium, phosphate, and calcium excretion were assessed in response to the Npt2a inhibitor in both groups of mice. Expression and localization of Npt2a/c and levels of plasma phosphate, calcium, parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF-23) were studied up to 24-hours after Npt2a-I treatment.
Results:
In normal mice, Npt2a inhibition caused a dose-dependent increase in urinary phosphate (ED50 approximately 21 mg/kg), calcium, sodium and chloride excretion. In contrast, urinary potassium excretion, flow rate and urinary pH were not affected dose dependently. Plasma phosphate and PTH significantly decreased after 3 hours, with both returning to near baseline levels after 24 hours. Similar effects were observed in the mouse model of CKD but were reduced in magnitude.
Conclusions:
Npt2a inhibition causes a dose-dependent increase in phosphate, sodium and chloride excretion associated with reductions in plasma phosphate and PTH levels in normal mice and in a CKD mouse model.
Insights
A new Npt2a inhibitor effectively increased phosphate excretion and lowered plasma phosphate levels in normal and chronic kidney disease (CKD) mouse models. This finding highlights a potential therapeutic target for managing hyperphosphatemia in CKD patients.
Area of Science:
- Nephrology
- Pharmacology
- Biochemistry
Background:
- Kidney function is crucial for phosphate homeostasis.
- Chronic kidney disease (CKD) often leads to hyperphosphatemia.
- Current treatments for hyperphosphatemia, including dietary restriction and phosphate binders, have limitations.
Purpose of the Study:
- To evaluate the efficacy of PF-06869206, an orally bioavailable Npt2a inhibitor, in normal and CKD mouse models.
- To assess the dose-dependent effects of Npt2a inhibition on urinary excretion of electrolytes and minerals.
- To investigate the impact of Npt2a inhibition on plasma levels of phosphate, PTH, and FGF-23.
Main Methods:
- Administered PF-06869206 to normal mice and a 5/6 subtotal nephrectomy (CKD) mouse model.
- Measured urinary excretion of sodium, chloride, potassium, phosphate, and calcium.
- Analyzed plasma phosphate, calcium, parathyroid hormone (PTH), and fibroblast growth factor 23 (FGF-23) levels.
Main Results:
- Npt2a inhibition dose-dependently increased urinary phosphate, calcium, sodium, and chloride excretion in normal mice.
- Plasma phosphate and PTH levels decreased significantly post-treatment, returning to baseline within 24 hours.
- Similar, though reduced in magnitude, effects were observed in the CKD mouse model.
Conclusions:
- Npt2a inhibition is a promising therapeutic strategy for managing hyperphosphatemia.
- The Npt2a inhibitor PF-06869206 demonstrated efficacy in both normal and CKD mouse models.
- Targeting Npt2a offers a potential new avenue for treating hyperphosphatemia in CKD patients.
Related Concept Videos
Reducing Line Loss
With a step-up transformer at the source, the voltage is increased, thereby reducing the current in the transmission lines since power loss in...
Methods of reducing fever
Pharmacological Methods of Reducing Fever:
Adaptations that Reduce Water Loss
Role of Reduced Coenzymes NADH and FADH₂
Redox Titration: Other Oxidizing and Reducing Agents
Reduced Mass Coordinates: Isolated Two-body Problem

